CELLECTIS
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.
CELLECTIS
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
1999-12-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.cellectis.com
Total Employee:
51+
Status:
Active
Contact:
+1 (347) 752-4044
Total Funding:
181.35 M USD
Technology used in webpage:
Domain Not Resolving ReCAPTCHA ReCAPTCHA V2 Apple Whitelist
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
CeNeS Pharmaceuticals
CeNeS Pharmaceuticals is a biopharmaceutical company that develops and commercializes.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
IntelliHep
IntelliHep is a spin-out company developing novel drugs for Alzheimers disease and cancer.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company with one approved product.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2011-09-15 | Cellartis | Cellartis acquired by Cellectis | N/A |
| 2010-09-09 | Cyto Pulse Sciences | Cyto Pulse Sciences acquired by Cellectis | 2.2 M USD |
Investors List
4BIO Capital
4BIO Capital investment in Post-IPO Equity - Cellectis
Andera Partners
Andera Partners investment in Series C - Cellectis
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Series C - Cellectis
ODYSSEE VENTURE
ODYSSEE VENTURE investment in Series C - Cellectis
Idinvest Partners
Idinvest Partners investment in Series C - Cellectis
Andera Partners
Andera Partners investment in Series B - Cellectis
Idinvest Partners
Idinvest Partners investment in Series B - Cellectis
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Series B - Cellectis
ODYSSEE VENTURE
ODYSSEE VENTURE investment in Series B - Cellectis
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-10 | Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer |
Official Site Inspections
http://www.cellectis.com Semrush global rank: 2.63 M Semrush visits lastest month: 6.52 K
- Host name: 178.16.164.60
- IP address: 178.16.164.60
- Location: Paris France
- Latitude: 48.8543
- Longitude: 2.3527
- Timezone: Europe/Paris
- Postal: 75011
